Clinical trial
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects…
NCT00321711 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00321711 |
|---|---|
| Title | Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents |
| Official title | A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | MDS, Myelodysplastic Syndromes, Thrombocytopenia |
| Intervention type | Biological, Drug |
| Interventions | Placebo, AMG 531 (Romiplostim), Azacitidine, Decitabine |
| Enrollment | 69 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 19, 2009 |
| Completion | Oct 19, 2009 |
| First posted | May 4, 2006 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: